#siRNA
Azt, szeretem a Linuxban, hogy ha valami nem is működik vagy lefagy akkor (eddigi tapasztalataim alapján) bármennyiszer simán restartolhatok (hard reboot) meg sem kottyan neki. A windows már sírna, hogy "nyenyenye az operációs rendszer rosszul lett leállítva! 😭".
November 17, 2026 at 2:57 PM
Regeneron joins crowded gMG field with four-dose-a-year siRNA #$REGN firstwordpharma.com/story/8462373
November 19, 2026 at 12:57 AM
Marrow raised $173M for an siRNA drug it hopes can compete with a one-time CRISPR therapy for sickle cell.
Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell
Marrow Therapeutics raised $173M to develop siRNA drug MAR-101 for sickle cell disease, as gene therapies Casgevy and Lyfgenia face sluggish sales.
endpoints.news
November 17, 2026 at 4:15 PM
DeepRNAi: Predicting on- and off-target siRNA activity and establishing a benchmark https://www.biorxiv.org/content/10.64898/2026.11.12.766311v1
November 13, 2026 at 7:31 PM
DeepRNAi: Predicting on- and off-target siRNA activity and establishing a benchmark https://www.biorxiv.org/content/10.64898/2026.11.12.766311v1
November 13, 2026 at 7:31 PM
I just published Beyond Uptake: In Vivo Quantification and Low Inflammation Engineering of LNP Endosomal Escape
medium.com/@medchemexpr...
Beyond Uptake: In Vivo Quantification and Low Inflammation Engineering of LNP Endosomal Escape
Lipid nanoparticles (LNPs) have enabled clinical mRNA vaccines, siRNA medicines and in vivo gene editing. However, for mRNA, siRNA and…
medium.com
November 19, 2026 at 10:12 AM
C3-targeting siRNA Combined with Oseltamivir Alleviates Inflammation and Lung Injury in H1N1-Infected Mice https://www.biorxiv.org/content/10.64898/2026.11.16.766876v1
November 17, 2026 at 3:19 PM
C3-targeting siRNA Combined with Oseltamivir Alleviates Inflammation and Lung Injury in H1N1-Infected Mice https://www.biorxiv.org/content/10.64898/2026.11.16.766876v1
November 17, 2026 at 3:19 PM
CRV Science News
🧬 Marrow Therapeutics Raises $173M for Bone Marrow-Targeted siRNA to Rival CRISPR in Sickle Cell Disease — Marrow Therapeutics, a Watertown, Massachusetts–based biotechnology company, emerged in November 2026 with…

https://crvscience.com/news/marrow-therapeutics-sirna-sickle-cell
CRV Science News 🧬 Marrow Therapeutics Raises $173M for Bone Marrow-Targeted siRNA to Rival CRISPR in Sickle Cell Disease — Marrow Therapeutics, a Watertown, Massachusetts–based biotechnology company, emerged in November 2026 with 173 million dollars in combined Series A and Series B financing to…
crvscience.com
November 18, 2026 at 8:43 AM


DeepRNAi: Predicting on- and off-target siRNA activity and establishing a benchmark

https://www.biorxiv.org/content/10.64898/2026.11.12.766311v1
November 16, 2026 at 1:57 PM
Targeted siRNA screening coupled with unbiased proteomics identify potassium signaling as a critical regulator of pigmentation https://www.biorxiv.org/content/10.64898/2026.11.13.766383v1
November 17, 2026 at 10:30 AM
A shocking twist in the sickle cell saga. Nearly 3 years after the FDA approved two one-and-done gene therapies for the disease, a new startup has raised $173M for siRNA drug, dosed chronically, that targets the same gene as the CRISPR therapy. @endpts.com: endpoints.news/marrow-raise...
Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell
Marrow Therapeutics raised $173M to develop siRNA drug MAR-101 for sickle cell disease, as gene therapies Casgevy and Lyfgenia face sluggish sales.
endpoints.news
November 17, 2026 at 2:50 PM
Targeted siRNA screening coupled with unbiased proteomics identify potassium signaling as a critical regulator of pigmentation https://www.biorxiv.org/content/10.64898/2026.11.13.766383v1
November 17, 2026 at 10:30 AM
October #JCLSpotlight: Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia
Read more: https://ow.ly/gnZh5107tnI
November 17, 2026 at 7:38 PM
NSUN2 siRNA combined with cisplatin promotes ferroptosis and inhibits the proliferation of cervical cancer cells by downregulating GOLPH3 expression

Neoplasma · Zhong et al.
doi.org/10.4149/neo_2026_260408n106
#RNAsky #RNAmods
NSUN2 siRNA combined with cisplatin promotes ferroptosis and inhibits the proliferation of cervical cancer cells by downregulating GOLPH3 expression
Neoplasma · Zhong J, Hong L, Zhou X, Chen G, Zou Y, Huang Q, Wang Z, Huang H.
doi.org
November 16, 2026 at 10:49 PM
🧬 New #preprint! Silscore: predicting #siRNA potency from thermodynamics and sequence. Led by Giuseppe Sacco, with Guido Sanguinetti, Giovanni Bussi and collaborators at Silthera and Univ. of L’Aquila. An interpretable model with strong predictive performance!

arxiv.org/abs/2611.15812
Silscore: modelling siRNA potency with positional thermodynamics and data-selected nucleotide-identity terms
Small interfering RNAs (siRNAs) enable programmable gene silencing, but candidates targeting the same transcript can differ markedly in potency. Existing predictors range from interpretable empirical ...
arxiv.org
November 13, 2026 at 8:08 AM
FDA Approves Livsayis As First siRNA Myasthenia Treatment
#TMLNews #Health #Wellness #PublicHealth #HealthNews
https://tml.news/stories/fda-approves-livsayis-cemdisiran-myasthenia-gravis/
Follow @tmlnews. The next story is already moving.
November 19, 2026 at 3:50 AM
Board and senior leadership changes

Dr Paloma Giangrande joins our Board as Non-Executive Director, and Dr James McNamara as Head of Oligonucleotide Therapeutic Development. Both helped pioneer aptamer-mediated siRNA delivery.

polaris.brighterir.com/public/aptam...

#APTA #RNA #aptamers
November 16, 2026 at 8:54 AM
happy #zakdornursday everyone. here is my all time favorite alien of the week: Sirna Kolrami. living proof that the federation will accept anyone no matter how annoying they are.
Star Trek: The Next Generation (1987)
Season 2, Episode 21: Peak Performance
Aired: 7/10/1989, Syndication
00:20:25.457
November 13, 2026 at 9:54 PM
Another Drug Shows Potential for Functional Cures in Chronic Hepatitis B
https://www.medpagetoday.com/meetingcoverage/aasld/123809
Another Drug Shows Potential for Functional Cures in Chronic Hepatitis B
With highest dose of siRNA therapy, 19% achieved a functional cure 24 weeks after treatment ended
www.medpagetoday.com
November 14, 2026 at 6:00 PM
Reductions in HBsAg were observed with a novel siRNA therapy in patients with chronic HBV infection, according to a phase II study.
https://www.medpagetoday.com/meetingcoverage/aasld/123809
Another Drug Shows Potential for Functional Cures in Chronic Hepatitis B
With highest dose of siRNA therapy, 19% achieved a functional cure 24 weeks after treatment ended
www.medpagetoday.com
November 10, 2026 at 6:59 PM
The firm is evaluating CITY-RBP4, an siRNA therapy designed to silence RBP4 expression, in a Phase I trial expected to initially read out in mid-2027.
City Therapeutics Launches Trial of RNAi Therapy for Stargardt Disease
City Therapeutics Launches Trial of RNAi Therapy for Stargardt Disease
ebx.sh
November 13, 2026 at 10:35 PM
Novel siRNA Therapeutic Cuts Liver Fat in MASLD, Early Trial Shows www.medpagetoday.com/meetingcover...
Novel siRNA Therapeutic Cuts Liver Fat in MASLD, Early Trial Shows
Liver fat percentages fell by up to 80% with highest treatment dose
www.medpagetoday.com
November 11, 2026 at 3:21 AM
Kumi Kawano and colleagues at Hoshi University demonstrate the antitumor activity of anionic polymer-coated polo-like kinase 1 siRNA lipoplexes.

Read their findings for free in RSC Pharmaceutics: pubs.rsc.org/pm/article/d...
November 12, 2026 at 11:21 AM